Statins and breast cancer stage and mortality in the Women’s Health Initiative

Cancer Causes and Control

Volumn 26, Issue 4, 2015, Pages 529-539

  Desai, Pinkal ^a   Lehman, Amy ^b   Chlebowski, Rowan T ^c   Kwan, Marilyn L ^d   Arun, Monica ^e   Manson, Jo Ann E ^f   Lavasani, Sayeh ^f   Wasswertheil Smoller, Sylvia ^g   Sarto, Gloria E ^h   LeBoff, Meryl ^f   Cauley, Jane ⁱ   Cote, Michele ^j   Beebe Dimmer, Jennifer ^j   Jay, Allison ^k   Simon, Michael S ^j  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d KAISER PERMANENTE   (United States)

^e BOSTON MEDICAL CENTER   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^h UNIVERSITY OF WISCONSIN MADISON   (United States)

ⁱ UNIVERSITY OF PITTSBURGH   (United States)

^j WAYNE STATE UNIVERSITY   (United States)

^k St John Medical Center   (United States)

more..

Author keywords

Breast cancer; Breast cancer mortality; Cancer stage; Statins

Indexed keywords

ATORVASTATIN; ESTROGEN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PROGESTERONE; SIMVASTATIN;

ADULT; AGED; ALCOHOLISM; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DIET THERAPY; DRUG POTENCY; ETHNICITY; FEMALE; HUMAN; HYDROPHILICITY; HYSTERECTOMY; LIPOPHILICITY; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MENARCHE; MITOCHONDRIAL MEMBRANE; MORBIDITY; OBSERVATIONAL STUDY; OVARIECTOMY; POPULATION RESEARCH; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; SMOKING; WAIST CIRCUMFERENCE; WOMEN'S HEALTH; BREAST NEOPLASMS; INCIDENCE; MIDDLE AGED; PATHOLOGY;

AGED; BREAST NEOPLASMS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MIDDLE AGED; NEOPLASM STAGING; RISK FACTORS; WOMEN'S HEALTH;

EID: 84925513669     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-015-0530-7     Document Type: Article

References (38)

1. www.cdc.gov/nchs/data/hus/hus10.pdf#fig17
2. Baigent C, Keech A, Kearney PM et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493):1267–1278
3. Goldstein JL, Brown MS (1990) Regulation of the mevalonate pathway. Nature 343(6257):425–430
4. Liao JK, Laufs U (2005) Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45:89–118
5. Liao JK (2002) Isoprenoids as mediators of the biological effects of statins. J Clin Invest 110(3):285–288
6. Wachtershauser A, Akoglu B, Stein J (2001) HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis 22(7):1061–1067
7. Agarwal B, Halmos B, Feoktistov AS et al (2002) Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells. Carcinogenesis 23(3):521–528
8. Spampanato C, De MS, Sarnataro M et al (2012) Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression. Int J Oncol 40(4):935–941
9. Cho SJ, Kim JS, Kim JM, Lee JY, Jung HC, Song IS (2008) Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer 123(4):951–957
10. Cauley JA, McTiernan A, Rodabough RJ et al (2006) Statin use and breast cancer: prospective results from the women’s health initiative. J Natl Cancer Inst 98(10):700–707
11. Pocobelli G, Newcomb PA, Trentham-Dietz A, Titus-Ernstoff L, Hampton JM, Egan KM (2008) Statin use and risk of breast cancer. Cancer 112(1):27–33
12. Haukka J, Sankila R, Klaukka T et al (2010) Incidence of cancer and statin usage—record linkage study. Int J Cancer 126(1):279–284
13. Desai P, Chlebowski R, Cauley JA et al (2013) Prospective analysis of association between statin use and breast cancer risk in the women’s health initiative. Cancer Epidemiol Biomarkers Prev 22(10):1868–1876
14. Kumar AS, Benz CC, Shim V, Minami CA, Moore DH, Esserman LJ (2008) Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomark Prev 17(5):1028–1033
15. Chae YK, Valsecchi ME, Kim J et al (2011) Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer Invest 29(9):585–593
16. Kwan ML, Habel LA, Flick ED, Quesenberry CP, Caan B (2008) Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat 109(3):573–579
17. Ahern TP, Pedersen L, Tarp M et al (2011) Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst 103(19):1461–1468
18. Nickels S, Vrieling A, Seibold P et al (2013) Mortality and recurrence risk in relation to the use of lipid-lowering drugs in a prospective breast cancer patient cohort. PLoS ONE 8(9):e75088
19. Nielsen SF, Nordestgaard BG, Bojesen SE (2012) Statin use and reduced cancer-related mortality. N Engl J Med 367(19):1792–1802
20. Design of the Women’s Health Initiative clinical trial and observational study. The Women’s Health Initiative Study Group (1998) Control Clin Trials 19(1):61–109
21. Anderson GL, Manson J, Wallace R et al (2003) Implementation of the women’s health initiative study design. Ann Epidemiol 13(9 Suppl):S5–17
22. Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA 288(3):321–333
23. Schachter M (2005) Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 19(1):117–125
24. Fong CW (2014) Statins in therapy: understanding their hydrophilicity, lipophilicity, binding to 3-hydroxy-3-methylglutaryl-CoA reductase, ability to cross the blood brain barrier and metabolic stability based on electrostatic molecular orbital studies. Eur J Med Chem 85C:661–674
25. Curb JD, McTiernan A, Heckbert SR et al (2003) Outcomes ascertainment and adjudication methods in the women’s health initiative. Ann Epidemiol 13(9 Suppl):S122–S128
26. Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94(446):496–509
27. Holstein SA, Wohlford-Lenane CL, Hohl RJ (2002) Isoprenoids influence expression of Ras and Ras-related proteins. Biochemistry 41(46):13698–13704
28. Duncan RE, El-Sohemy A, Archer MC (2005) Statins and cancer development. Cancer Epidemiol Biomarkers Prev 14(8):1897–1898
29. Seasholtz TM, Majumdar M, Brown JH (1999) Rho as a mediator of G protein-coupled receptor signaling. Mol Pharmacol 55(6):949–956
30. Denoyelle C, Vasse M, Korner M et al (2001) Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 22(8):1139–1148
31. Bardou M, Barkun A, Martel M (2010) Effect of statin therapy on colorectal cancer. Gut 59(11):1572–1585
32. Asakage M, Tsuno NH, Kitayama J et al (2004) 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (pravastatin) inhibits endothelial cell proliferation dependent on G1 cell cycle arrest. Anticancer Drugs 15(6):625–632
33. Keyomarsi K, Sandoval L, Band V, Pardee AB (1991) Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 51(13):3602–3609
34. Alonso DF, Farina HG, Skilton G, Gabri MR, De Lorenzo MS, Gomez DE (1998) Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 50(1):83–93
35. Farina HG, Bublik DR, Alonso DF, Gomez DE (2002) Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells. Clin Exp Metastasis 19(6):551–559
36. Cauley JA, Zmuda JM, Lui LY et al (2003) Lipid-lowering drug use and breast cancer in older women: a prospective study. J Womens Health (Larchmt) 12(8):749–756
37. Boudreau DM, Gardner JS, Malone KE, Heckbert SR, Blough DK, Daling JR (2004) The association between 3-hydroxy-3-methylglutaryl coenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case–control study. Cancer 100(11):2308–2316
38. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM (2005) Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 23(34):8606–8612